Subtype-specific KRAS mutations in advanced lung adenocarcinoma: A retrospective study of patients treated with platinum-based chemotherapy

European Journal of Cancer

Volumn 50, Issue 10, 2014, Pages 1819-1828

  Cserepes, Mihaly ^a,b   Ostoros, Gyula ^a   Lohinai, Zoltan ^a,b   Raso, Erzsebet ^c,d   Barbai, Tamas ^c   Timar, Jozsef ^c,d   Rozsas, Anita ^a,b   Moldvay, Judit ^c   Kovalszky, Ilona ^c   Fabian, Katalin ^c   Gyulai, Marton ^e   Ghanim, Bahil ^b,f   Laszlo, Viktoria ^b   Klikovits, Thomas ^b   Hoda, Mir Alireza ^b,f   Grusch, Michael ^f   Berger, Walter ^f   Klepetko, Walter ^b   Hegedus, Balazs ^b,c,d   Dome, Balazs ^a,b,c  

^a NATIONAL KORANYI INSTITUTE OF PULMONOLOGY   (Hungary)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c SEMMELWEIS UNIVERSITY   (Hungary)

^d INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^e Pest County Institute of Pulmonology   (Hungary)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Advanced stage lung adenocarcinoma; KRAS mutation; Non small cell lung cancer; Platinum based chemotherapy

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; PACLITAXEL; PEMETREXED;

ADULT; ADVANCED CANCER; AMINO ACID SUBSTITUTION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CAUCASIAN; CODON; CONTROLLED STUDY; EASTERN COOPERATIVE ONCOLOGY GROUP STATUS; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; ONCOGENE K RAS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SMOKING; TREATMENT RESPONSE; WILD TYPE;

ADVANCED-STAGE LUNG ADENOCARCINOMA; KRAS MUTATION; NON-SMALL CELL LUNG CANCER; PLATINUM-BASED CHEMOTHERAPY;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHI-SQUARE DISTRIBUTION; CISPLATIN; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HUNGARY; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; NEOPLASM STAGING; PATIENT SELECTION; PHENOTYPE; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RETROSPECTIVE STUDIES; RISK FACTORS; SMOKING; TIME FACTORS; TREATMENT OUTCOME;

EID: 84901787925     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2014.04.001     Document Type: Article

References (49)

1. K. Suda, K. Tomizawa, and T. Mitsudomi Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation Cancer Metastasis Rev 29 1 2010 49 60
2. J.C. Smith, L. Brooks, P.M. Hoff, G. McWalter, S. Dearden, and S.R. Morgan et al. KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib Eur J Cancer 49 10 2013 2424 2432
3. J.L. Bos Ras oncogenes in human cancer - a review Cancer Res 49 17 1989 4682 4689
4. I.A. Prior, P.D. Lewis, and C. Mattos A comprehensive survey of Ras mutations in cancer Cancer Res 72 10 2012 2457 2467
5. S. Aviel-Ronen, F.H. Blackhall, F.A. Shepherd, and M.S. Tsao K-ras mutations in non-small-cell lung carcinoma: a review Clin Lung Cancer 8 1 2006 30 38
6. A. Lievre, J.B. Bachet, D. Le Corre, V. Boige, B. Landi, and J.F. Emile et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer Cancer Res 66 8 2006 3992 3995
7. C.S. Karapetis, S. Khambata-Ford, D.J. Jonker, C.J. O'Callaghan, D. Tu, and N.C. Tebbutt et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer N Engl J Med 359 17 2008 1757 1765
8. R.G. Amado, M. Wolf, M. Peeters, E. Van Cutsem, S. Siena, and D.J. Freeman et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 26 10 2008 1626 1634
9. S. Khambata-Ford, C.T. Harbison, L.L. Hart, M. Awad, L.A. Xu, and C.E. Horak et al. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer J Clin Oncol 28 6 2010 918 927
10. K.J. O'Byrne, U. Gatzemeier, I. Bondarenko, C. Barrios, C. Eschbach, and U.M. Martens et al. Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study Lancet Oncol 12 8 2011 795 805
11. R. Pirker, J.R. Pereira, J. von Pawel, M. Krzakowski, R. Ramlau, and K. Park et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study Lancet Oncol 13 1 2012 33 42
12. R. Pirker EGFR-directed monoclonal antibodies in non-small cell lung cancer Target Oncol 8 1 2013 47 53
13. H. Linardou, I.J. Dahabreh, D. Kanaloupiti, F. Siannis, D. Bafaloukos, and P. Kosmidis et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer Lancet Oncol 9 10 2008 962 972
14. C. Mao, L.X. Qiu, R.Y. Liao, F.B. Du, H. Ding, and W.C. Yang et al. KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies Lung Cancer 69 3 2010 272 278
15. P.J. Roberts, and T.E. Stinchcombe KRAS mutation: should we test for it, and does it matter? J Clin Oncol 31 8 2013 1112 1121
16. P. Martin, N.B. Leighl, M.S. Tsao, and F.A. Shepherd KRAS mutations as prognostic and predictive markers in non-small cell lung cancer J Thorac Oncol 8 5 2013 530 542
17. C. Mascaux, N. Iannino, B. Martin, M. Paesmans, T. Berghmans, and M. Dusart et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis Brit J Cancer 92 1 2005 131 139
18. S. Rodenhuis, L. Boerrigter, B. Top, R.J. Slebos, W.J. Mooi, and L. van't Veer et al. Mutational activation of the K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study J Clin Oncol 15 1 1997 285 291
19. D.A. Eberhard, B.E. Johnson, L.C. Amler, A.D. Goddard, S.L. Heldens, and R.S. Herbst et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib J Clin Oncol 23 25 2005 5900 5909
20. M.S. Tsao, S. Aviel-Ronen, K. Ding, D. Lau, N. Liu, and A. Sakurada et al. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer J Clin Oncol 25 33 2007 5240 5247
21. T. Winton, R. Livingston, D. Johnson, J. Rigas, M. Johnston, and C. Butts et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer N Engl J Med 352 25 2005 2589 2597
22. V. Bazan, V. Agnese, S. Corsale, V. Calo, M.R. Valerio, and M.A. Latteri et al. Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year Gruppo Oncologico dell'Italia Meridionale (GOIM) prospective study Ann Oncol 16 Suppl. 4 2005 iv50 55
23. W. De Roock, D.J. Jonker, F. Di Nicolantonio, A. Sartore-Bianchi, D. Tu, and S. Siena et al. Association of KRAS p. G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab JAMA 304 16 2010 1812 1820
24. S. Tejpar, I. Celik, M. Schlichting, U. Sartorius, C. Bokemeyer, and E. Van Cutsem Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab J Clin Oncol 30 29 2012 3570 3577
25. J.Y. Douillard, K.S. Oliner, S. Siena, J. Tabernero, R. Burkes, and M. Barugel et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer N Engl J Med 369 11 2013 1023 1034
26. R.J. Slebos, R.E. Kibbelaar, O. Dalesio, A. Kooistra, J. Stam, and C.J. Meijer et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung N Engl J Med 323 9 1990 561 565
27. R. Rosell, S. Li, Z. Skacel, J.L. Mate, J. Maestre, and M. Canela et al. Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients Oncogene 8 9 1993 2407 2412
28. T. Mitsudomi, S.M. Steinberg, H.K. Oie, J.L. Mulshine, R. Phelps, and J. Viallet et al. Ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent Cancer Res 51 18 1991 4999 5002
29. M.C. Garassino, M. Marabese, P. Rusconi, E. Rulli, O. Martelli, and G. Farina et al. Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer Ann Oncol 22 1 2011 235 237
30. L.C. Villaruz, M.A. Socinski, D.E. Cunningham, S.I. Chiosea, T.F. Burns, and J.M. Siegfried et al. The prognostic and predictive value of KRAS oncogene substitutions in lung adenocarcinoma Cancer 119 12 2013 2268 2274
31. F.A. Shepherd, C. Domerg, P. Hainaut, P.A. Janne, J.P. Pignon, and S. Graziano et al. Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy J Clin Oncol 31 17 2013 2173 2181
32. P. Goldstraw, J. Crowley, K. Chansky, D.J. Giroux, P.A. Groome, and R. Rami-Porta et al. The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours J Thorac Oncol 2 8 2007 706 714
33. N.I. Lindeman, P.T. Cagle, M.B. Beasley, D.A. Chitale, S. Dacic, and G. Giaccone et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology Arch Pathol Lab Med 137 6 2013 828 860
34. B. Szabo, G.A. Nelhubel, A. Karpati, I. Kenessey, B. Jori, and C. Szekely et al. Clinical significance of genetic alterations and expression of epidermal growth factor receptor (EGFR) in head and neck squamous cell carcinomas Oral Oncol 47 6 2011 487 496
35. S. Bamford, E. Dawson, S. Forbes, J. Clements, R. Pettett, and A. Dogan et al. The COSMIC (catalogue of somatic mutations in cancer) database and website Br J Cancer 91 2 2004 355 358
36. W.W. Mellema, A.M. Dingemans, E. Thunnissen, P.J. Snijders, J. Derks, and D.A. Heideman et al. KRAS mutations in advanced nonsquamous non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy have no predictive value J Thorac Oncol 8 9 2013 1190 1195
37. J.M. Sun, D.W. Hwang, J.S. Ahn, M.J. Ahn, and K. Park Prognostic and predictive value of KRAS mutations in advanced non-small cell lung cancer PLoS One 8 5 2013 e64816
38. H.A. Yu, C.S. Sima, R. Shen, S.L. Kass, M.G. Kris, and M. Ladanyi et al. Comparison of the characteristics and clinical course of 677 patients with metastatic lung cancers with mutations in KRAS codons 12 and 13 J Clin Oncol 31 Suppl. 2013 [abstr 8025]
39. Y. Imamura, T. Morikawa, X. Liao, P. Lochhead, A. Kuchiba, and M. Yamauchi et al. Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers Clin Cancer Res 18 17 2012 4753 4763
40. G.J. Riely, M.G. Kris, D. Rosenbaum, J. Marks, A. Li, and D.A. Chitale et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma Clin Cancer Res 14 18 2008 5731 5734
41. K. Husgafvel-Pursiainen, P. Hackman, M. Ridanpaa, S. Anttila, A. Karjalainen, and T. Partanen et al. K-ras mutations in human adenocarcinoma of the lung: association with smoking and occupational exposure to asbestos Int J Cancer 53 2 1993 250 256
42. H.R. Kim, J.R. Ahn, J.G. Lee, D.H. Bang, S.J. Ha, and Y.K. Hong et al. The Impact of cigarette smoking on the frequency of and qualitative differences in KRAS mutations in korean patients with lung adenocarcinoma Yonsei Med J 54 4 2013 865 874
43. S. Torok, B. Hegedus, V. Laszlo, M.A. Hoda, B. Ghanim, and W. Berger et al. Lung cancer in never smokers Future Oncol 7 10 2011 1195 1211
44. C.K. Toh, E.H. Wong, W.T. Lim, S.S. Leong, K.W. Fong, and J. Wee et al. The impact of smoking status on the behavior and survival outcome of patients with advanced non-small cell lung cancer: a retrospective analysis Chest 126 6 2004 1750 1756
45. C.M. Tammemagi, C. Neslund-Dudas, M. Simoff, and P. Kvale Smoking and lung cancer survival: the role of comorbidity and treatment Chest 125 1 2004 27 37
46. L.T. Nordquist, G.R. Simon, A. Cantor, W.M. Alberts, and G. Bepler Improved survival in never-smokers vs current smokers with primary adenocarcinoma of the lung Chest 126 2 2004 347 351
47. R.S. Herbst, D. Prager, R. Hermann, L. Fehrenbacher, B.E. Johnson, and A. Sandler et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer J Clin Oncol 23 25 2005 5892 5899
48. A.S. Tsao, D. Liu, J.J. Lee, M. Spitz, and W.K. Hong Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer Cancer 106 11 2006 2428 2436
49. G.V. Scagliotti, P. Parikh, J. von Pawel, B. Biesma, J. Vansteenkiste, and C. Manegold et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer J Clin Oncol 26 21 2008 3543 3551